A great need exists for the development of new medications to treat pain resulting from
various disease states and types of injury. Given that the endogenous cannabinoid (that is …

Cannabinoids, when co-administered with opioids, may enable reduced opioid doses
without loss of analgesic efficacy (ie, an opioid-sparing effect). The aim of this study was to …

Cannabinoid co-administration may enable reduced opioid doses for analgesia. This
updated systematic review on the opioid-sparing effects of cannabinoids considered …

Introduction: The opioid epidemic has become an immense problem in North America, and
despite decades of research on the most effective means to treat opioid use disorder (OUD) …

Human tissues express cannabinoid CB1 and CB2 receptors that can be activated by
endogenously released 'endocannabinoids' or exogenously administered compounds in a …

Mandarin translation of abstract Medicines that activate cannabinoid CB1 and CB2 receptor
are already in the clinic. These are Cesamet®(nabilone), Marinol®(dronabinol; Δ9 …

Cannabinoids combined with opioids produce synergistic antinociceptive effects,
decreasing the lowest effective antinociceptive opioid dose (ie, opioid-sparing effects) in …

Background Approximately 18% of patients with cancer use cannabis at one time as
palliation or treatment for their cancer. We performed a systematic review of randomized …

This paper is the 28th consecutive installment of the annual review of research concerning
the endogenous opioid system, now spanning over a quarter-century of research. It …

Cannabis derivatives have become the most widely used illicit substances in developed
countries, and constitute a major health concern. The psychoactive compounds contained in …